A Look At Payers' Early Game Plans For Driving Biosimilar Use
Executive Summary
Interviews with US payers suggest that at first they are more likely to focus on promoting biosimilars in treatment-naïve patients, as opposed to switching those on branded drugs, according to a new Datamonitor report.